Sahajanand Medical Technologies

Sahajanand Medical Technologies (SMT) is a prominent developer and manufacturer of minimally invasive coronary stent systems, renowned for its extensive product range. With a presence in over 75 countries, SMT stands as a strong international player in the industry. The company prides itself on continuous innovation and portfolio enhancement to meet diverse healthcare needs. Committed to advancing patient care, SMT focuses on introducing cutting-edge medical devices to save lives globally. Notably, SMT achieved the distinction of being the first company to secure a CE mark for biodegradable polymer-based drug-eluting stents, indicative of its pioneering approach. Its portfolio encompasses drug-eluting stents, bare metal stents, balloon catheters, and inflation devices. With a philosophy centered on "PLEDGED TO SAVE MILLIONS," SMT is dedicated to the welfare of patients worldwide. Established in 1998 and headquartered in India, SMT has recently attracted significant attention from investors. In a recent Secondary Market investment on 09 January 2023, the company secured funding from Axiom Asia Private Capital, StepStone Group, TR Capital, and Unigestion, underscoring the confidence these notable investors have in SMT's innovative and impactful endeavors within the Developer Tools and Manufacturing sectors.